PDSB | tickerfilter.com

Fundamental analysis

17%

Profitability 8%

Dept financing 15%

Liquidity 50%

Performance 20%

Company vs Stock growth

N/A

2.250 1.250

-1.000 -44.44%

+ Add row to compare

Performance

5 Days

-1.58%

1 Month

-22.08%

3 Months

-33.68%

6 Months

-72.50%

1 Year

-71.40%

2 Year

-84.28%

Key data

Stock price

$0.94

P/E Ratio

0.00

DAY RANGE

$0.92 - $1.02

EPS

-$1.09

52 WEEK RANGE

$0.85 - $4.42

52 WEEK CHANGE

-$70.31

MARKET CAP

60.977 M

YIELD

N/A

SHARES OUTSTANDING

36.820 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-14-2025

BETA

3.32

PUBLIC FLOAT

AVERAGE 10 VOLUME

$347,377

AVERAGE 30 VOLUME

$350,592

Company detail

CEO: Frank K. Bedu-Addo
Region: US
Website: pdsbiotech.com
Employees: 20
IPO year: 2015

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

PDS Biotechnology Corporation focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials.

PDSB - PDS Biotechnology Corp